Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Morgan Stanley has upgraded Gilead Sciences (GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. Read more here.
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
Hosted on MSN1d
Drugmakers Just Hiked Prices for Over 500 MedicinesPharmaceutical companies just raised list prices for over 500 medicines, including Novo Nordisk’s Ozempic, Gilead’s HIV-1 ...
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...
Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback